EMBECTA CORP (EMBC) Stock Price, Quote, News and Overview
NASDAQ:EMBC - Nasdaq - US29082K1051 - Common Stock - Currency: USD
EMBC Quote, Performance and Key Statistics
14.1
-0.31 (-2.15%)
The current stock price of EMBC is 14.1 USD. In the past month the price decreased by -26.29%. In the past year, price decreased by -4.99%.
EMBC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ALC | ALCON INC | 29.9 | 45.13B | ||
| COO | COOPER COS INC/THE | 23.91 | 17.66B | ||
| ALGN | ALIGN TECHNOLOGY INC | 20.39 | 14.22B | ||
| SOLV | SOLVENTUM CORP | 17.55 | 12.61B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 30.7 | 6.01B | ||
| BLCO | BAUSCH + LOMB CORP | 25.4 | 5.55B | ||
| LNTH | LANTHEUS HOLDINGS INC | 11.27 | 5.44B | ||
| ICUI | ICU MEDICAL INC | 27.69 | 3.85B | ||
| XRAY | DENTSPLY SIRONA INC | 10.14 | 3.73B | ||
| HAE | HAEMONETICS CORP/MASS | 14.9 | 3.17B | ||
| NEOG | NEOGEN CORP | 25.1 | 2.18B | ||
| UFPT | UFP TECHNOLOGIES INC | 36.31 | 1.95B |
Related stock screener links
About EMBC
Company Profile
Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. The company is headquartered in Parsippany, New Jersey and currently employs 2,200 full-time employees. The company went IPO on 2022-03-21. The company is focused on providing solutions to people living with diabetes. The company has a portfolio of products, including a range of pen needles, syringes and safety injection devices, which are complemented by its digital application designed to assist people with managing their diabetes. Its pen needles are sterile, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. The company sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. In addition to pen needles, it sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. The company has clearance from the FDA for its proprietary disposable insulin delivery system, which is indicated for adults who require insulin to manage diabetes, including both type 1 (T1D) and type 2 (T2D).
Company Info
EMBECTA CORP
300 Kimball Drive, Suite 300
Parsippany NEW JERSEY US
Employees: 2200
Company Website: https://www.embecta.com/
Investor Relations: https://investors.embecta.com/
Phone: 18624010000
EMBECTA CORP / EMBC FAQ
What is the stock price of EMBECTA CORP today?
The current stock price of EMBC is 14.1 USD. The price decreased by -2.15% in the last trading session.
What is the ticker symbol for EMBECTA CORP stock?
The exchange symbol of EMBECTA CORP is EMBC and it is listed on the Nasdaq exchange.
On which exchange is EMBC stock listed?
EMBC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for EMBECTA CORP stock?
11 analysts have analysed EMBC and the average price target is 21.47 USD. This implies a price increase of 52.28% is expected in the next year compared to the current price of 14.1. Check the EMBECTA CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EMBECTA CORP worth?
EMBECTA CORP (EMBC) has a market capitalization of 819.63M USD. This makes EMBC a Small Cap stock.
How many employees does EMBECTA CORP have?
EMBECTA CORP (EMBC) currently has 2200 employees.
What are the support and resistance levels for EMBECTA CORP (EMBC) stock?
EMBECTA CORP (EMBC) has a support level at 13.81 and a resistance level at 16.35. Check the full technical report for a detailed analysis of EMBC support and resistance levels.
Is EMBECTA CORP (EMBC) expected to grow?
The Revenue of EMBECTA CORP (EMBC) is expected to decline by -0.97% in the next year. Check the estimates tab for more information on the EMBC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy EMBECTA CORP (EMBC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EMBC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EMBC, evaluating the profitability, health, valuation and growth aspects
- EMBECTA CORP (EMBC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EMBECTA CORP (EMBC) Sales and EPS estimates to see what analysts future expectations are.
- EMBECTA CORP (EMBC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EMBECTA CORP (EMBC) Insider and Institutional Ownership to learn about the owners and their transactions.
- EMBECTA CORP (EMBC) Stock Chart to make your own analysis
- EMBECTA CORP (EMBC) Latest news and press-releases to stay up to date.
Does EMBECTA CORP (EMBC) stock pay dividends?
EMBECTA CORP (EMBC) has a dividend yield of 4.16%. The yearly dividend amount is currently 0.6. Check the full fundamental report for a detailed analysis of EMBC dividend history, reliability and sustainability.
When does EMBECTA CORP (EMBC) report earnings?
EMBECTA CORP (EMBC) will report earnings on 2025-05-07, before the market open.
What is the Price/Earnings (PE) ratio of EMBECTA CORP (EMBC)?
The PE ratio for EMBECTA CORP (EMBC) is 5.62. This is based on the reported non-GAAP earnings per share of 2.51 and the current share price of 14.1 USD. Check the full fundamental report for a full analysis of the valuation metrics for EMBC.
What is the Short Interest ratio of EMBECTA CORP (EMBC) stock?
The outstanding short interest for EMBECTA CORP (EMBC) is 2.36% of its float. Check the ownership tab for more information on the EMBC short interest.
EMBC Technical Analysis
EMBC Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to EMBC. While EMBC belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
EMBC Financial Highlights
Over the last trailing twelve months EMBC reported a non-GAAP Earnings per Share(EPS) of 2.51. The EPS increased by 47.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 5.25% | ||
| ROA | 5.06% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
EMBC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to EMBC. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 16.04% and a revenue growth -0.97% for EMBC